CMS revives effort to pay hospitals less for drugs from 340B program  

CMS is proposing new Medicare reimbursement cuts for outpatient drugs hospitals buy through the 340B program, reviving a policy the Supreme Court previously blocked.

What you’ll learn

• How CMS is proposing to change Medicare payments for 340B-acquired drugs
• Why newly collected hospital acquisition cost data is central to the proposal
• What the rule could mean for hospitals, beneficiaries and potential litigation

Why this matters

The 340B program sits at the center of debates over drug pricing, hospital reimbursement and access to care. POLITICO Pro helps health care organizations track how CMS rulemaking, legal risk and stakeholder response could shape strategy, planning and advocacy.

Fill out the form to read the full POLITICO Pro article.